BioInvent

279 articles with BioInvent

• BioInvent Issues Statement Confirming that it does not Hold Cash Deposits or Securities at Silicon Valley Bank

  3/13/2023

  BioInvent International AB, a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, informed its shareholders that BioInvent does not hold cash deposits or securities at Silicon Valley Bank, or any other foreign bank.

• BioInvent International AB Year-End Report January 1 - December 31, 2022

  2/22/2023

  BioInvent made significant advances in 2022, further developing our exciting pipeline of novel and first-in-class immuno-modulatory antibodies for cancer therapy and substantially reinforcing the company's financial position.

• Change in the Number of Shares and Votes in BioInvent International AB - Jan 31, 2023

  1/31/2023

  BioInvent International AB announced that the company's total number of shares as per January 31, 2023 amounts to 65,804,362 shares, corresponding to an equal number of votes.

• Nomination Committee Appointed for BioInvent International’s Annual General Meeting 2023

  12/19/2022

  The members of the Nomination Committee for BioInvent International AB:s Annual General Meeting in 2023 have now been appointed.

• BioInvent Initiates Phase 1 Trial with Subcutaneous Formulation of BI-1206

  12/19/2022

  BioInvent International AB today announces the inclusion of the first patient in a Phase 1 trial with a subcutaneous formulation of its lead drug candidate, the novel anti-FcyRIIB antibody BI-1206.

• BioInvent Outlines Strong Progress in Clinical and Preclinical Pipeline at R&D Day 2022

  12/8/2022

  BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies for cancer immunotherapy, today provides an update on its clinical and pre-clinical pipeline, including an update on its lead drug candidate, the novel anti-FcγRIIB antibody BI-1206.

• Transgene and BioInvent Joint Paper on BT-001 Wins JITC “Best Oncolytic and Local Immunotherapy Paper” Award for 2022

  11/14/2022

  Transgene and BioInvent International AB announced that a paper co-authored by researchers from Transgene and BioInvent is the recipient of this year’s Journal for ImmunoTherapy of Cancer “Best Oncolytic and Local Immunotherapy Paper” Award.

• BioInvent International AB: Interim report January-September 2022

  10/27/2022

  BioInvent further strengthened its financial position in the third quarter through a directed share issue.

• Invitation to Presentation of BioInvent's Interim Report January - September 2022 on October 27, 2022

  10/24/2022

  BioInvent International - BioInvent International AB invites to a presentation of the Q3 interim report and a telephone conference with CEO Martin Welschof and CFO Stefan Ericsson.

• BioInvent Completes the Planned Dose-Escalation in Phase 1/2a trial of BI-1808 in Advanced Malignancies

  9/6/2022

  BioInvent International AB announces the completion of the planned dose escalation part of its Phase 1/2a trial of the anti-TNFR2 drug candidate BI-1808.

• BioInvent International AB: Interim Report January-June 2022

  8/25/2022

  The second quarter 2022 was eventful for BioInvent, delivering a deal with the US biotech company Exelixis, positive progress in our clinical portfolio and strengthened organizational leadership.

• BioInvent Enrolls First Patient in Phase 1/2a Trial of BI-1607 in HER2 Positive Solid Tumors

  8/1/2022

  BioInvent International AB announces treatment of the first patient in a Phase 1/2a trial of its second anti-FcyRIIB antibody BI-1607 in combination with trastuzumab in HER2+ solid tumors.

• Change in the Number of Shares and Votes in BioInvent International AB

  7/29/2022

  BioInvent International AB announced that the company's total number of shares as per July 29, 2022 amounts to 64,967,884 shares, corresponding to an equal number of votes.

• Resolutions at the Extraordinary General Meeting in BioInvent on July 12, 2022

  7/12/2022

  BioInvent International today resolved to elect Natalie Berner and Nanna Luneborg as new Board members.

• BioInvent and Transgene Announce Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BT-001 in Combination with KEYTRUDA(R)

  6/28/2022

  BioInvent International AB and Transgene announced a clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Rahway, NJ., USA, to evaluate the oncolytic virus BT-001 in combination with MSD's anti-PD-1 therapy KEYTRUDA® in a Phase 1/2a clinical trial for the treatment of patients with solid tumors.

• Transgene and BioInvent Announce Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BT-001 in Combination with KEYTRUDA®

  6/28/2022

  Transgene and BioInvent International AB announced a clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Rahway, NJ., USA, to evaluate the oncolytic virus BT-001 in combination with MSD’s anti-PD-1 therapy KEYTRUDA® in a Phase I/IIa clinical trial for the treatment of patients with solid tumors.

• Transgene and BioInvent Announce Positive Progress for BT-001

  6/27/2022

  Transgene and BioInvent International AB jointly announced positive progress and safety data of the ongoing Phase I/IIa trial evaluating BT-001 in patients with solid tumors, including melanoma.

• 

  ADC Space Continues to Thrive with Four More Companies Linking Up

  6/16/2022

  This week sees Exelixis, BioInvent, ImmunoGen and Oxford BioTherapeutics coming together to develop antibody-based therapies for cancer.

• Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology Therapies

  6/16/2022

  Exelixis, Inc. and BioInvent International AB announced that the companies have entered into an option and license agreement focused on the identification and development of novel antibodies for use in IO therapeutics.

• Natalie Berner of Redmile and Nanna Lüneborg of Forbion proposed as New Board Members of BioInvent

  6/16/2022

  BioInvent International AB announces on behalf of the nomination committee, the proposal to elect Natalie Berner and Nanna Lüneborg as new Board members, at the Extraordinary General Meeting on July 12, 2022.